Foundations Investment Advisors LLC Buys 6,588 Shares of Abbott Laboratories $ABT

Foundations Investment Advisors LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 60.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,429 shares of the healthcare product maker’s stock after purchasing an additional 6,588 shares during the period. Foundations Investment Advisors LLC’s holdings in Abbott Laboratories were worth $2,334,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ABT. Charles Schwab Trust Co increased its stake in shares of Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after purchasing an additional 15,394 shares during the last quarter. Asset Management One Co. Ltd. increased its position in Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after buying an additional 19,966 shares during the last quarter. Nordea Investment Management AB raised its stake in Abbott Laboratories by 6.1% in the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after buying an additional 18,974 shares during the period. Seaview Investment Managers LLC acquired a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $11,068,000. Finally, iA Global Asset Management Inc. boosted its stake in shares of Abbott Laboratories by 94.0% during the 3rd quarter. iA Global Asset Management Inc. now owns 144,062 shares of the healthcare product maker’s stock worth $19,296,000 after acquiring an additional 69,803 shares during the period. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ABT. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Barclays increased their price objective on shares of Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Jefferies Financial Group raised their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. BTIG Research decreased their price target on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Daiwa Capital Markets raised their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $140.75.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $109.31 on Friday. The firm has a 50 day moving average of $122.77 and a 200-day moving average of $127.49. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $190.08 billion, a PE ratio of 29.39, a PEG ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the firm posted $1.34 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s payout ratio is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.